<div><!-- source: https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/LOKELMA-myAZ-integration_Phase4?node-id=677-7514 --><div class="hero-banner"><div><div><picture><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/41b14afc6408fc20d6abf3107dd5af6ecdfc7bd4.png"><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/41b14afc6408fc20d6abf3107dd5af6ecdfc7bd4.png" media="(min-width: 600px)"><img src="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/41b14afc6408fc20d6abf3107dd5af6ecdfc7bd4.png" alt="Banner Background" loading="lazy"></picture></div></div><div><div><h1 id="about-hyperkalemia">About Hyperkalemia</h1></div></div></div></div>
<div><h2 id="hyperkalemia-is-an-electrolyte-disorder1">Hyperkalemia is an electrolyte disorder<sup>1</sup></h2></div>
<div><h3 id="predisposing-factors1-5">Predisposing factors:<sup>1-5</sup></h3><div class="columns-factors"><div><div><picture><source srcset="https://www.figma.com/content/images/hyperkalemia/933c398694871c3b53aa5d288df8340ab35da643.png"><source srcset="https://www.figma.com/content/images/hyperkalemia/933c398694871c3b53aa5d288df8340ab35da643.png" media="(min-width: 600px)"><img src="https://www.figma.com/content/images/hyperkalemia/933c398694871c3b53aa5d288df8340ab35da643.png" alt="" loading="lazy"></picture> <strong>HF</strong></div><div><picture><source srcset="https://www.figma.com/content/images/hyperkalemia/dd337acbe12d50de291c9c3767f3b4349bb53c89.png"><source srcset="https://www.figma.com/content/images/hyperkalemia/dd337acbe12d50de291c9c3767f3b4349bb53c89.png" media="(min-width: 600px)"><img src="https://www.figma.com/content/images/hyperkalemia/dd337acbe12d50de291c9c3767f3b4349bb53c89.png" alt="" loading="lazy"></picture> <strong>T2D</strong></div><div><picture><source srcset="https://www.figma.com/content/images/hyperkalemia/51dbe19dbb9f912d8682a8bdd8f83bc00546717d.png"><source srcset="https://www.figma.com/content/images/hyperkalemia/51dbe19dbb9f912d8682a8bdd8f83bc00546717d.png" media="(min-width: 600px)"><img src="https://www.figma.com/content/images/hyperkalemia/51dbe19dbb9f912d8682a8bdd8f83bc00546717d.png" alt="" loading="lazy"></picture> <strong>CKD</strong></div><div>Concomitant<br><strong>RAASi</strong><br>use</div></div></div></div>
<div><p>In studies, the incidence of hyperkalemia over follow-up duration of approximately 1 year was observed to be:<sup>6</sup></p></div>
<div><div class="columns-statistics"><div><div><p><picture><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/7617fc50df3a42e2e2e9e62c9eff90c7b9c91fb9.svg"><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/7617fc50df3a42e2e2e9e62c9eff90c7b9c91fb9.svg" media="(min-width: 600px)"><img src="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/7617fc50df3a42e2e2e9e62c9eff90c7b9c91fb9.svg" alt="Pie chart showing less than 5 percent" loading="lazy"></picture></p><p><strong>&#x3C;5%</strong><br>with<br><strong>HF</strong></p></div><div><p><picture><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/d10de9d95a6f4194623aee1bc4f0e180d7705b31.svg"><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/d10de9d95a6f4194623aee1bc4f0e180d7705b31.svg" media="(min-width: 600px)"><img src="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/d10de9d95a6f4194623aee1bc4f0e180d7705b31.svg" alt="Pie chart showing 40 percent" loading="lazy"></picture></p><p><strong>Up to</strong><br><strong>40%</strong><br>with<br><strong>chronic HF</strong></p></div><div><p><picture><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/65f7720faae2f19639fd728c201ae8a9ed58ffde.svg"><source srcset="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/65f7720faae2f19639fd728c201ae8a9ed58ffde.svg" media="(min-width: 600px)"><img src="https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/images/hyperkalemia/65f7720faae2f19639fd728c201ae8a9ed58ffde.svg" alt="Pie chart showing approximately 73 percent" loading="lazy"></picture></p><p><strong>~73%</strong><br>with<br><strong>CKD</strong></p></div></div></div></div>
<div><div class="columns-callout"><div><div>Diabetes Canada guidelines recommend sodium zirconium<br>cyclosilicate as a treatment option in patients with moderate to<br>high potassium<sup>1</sup></div></div></div></div>
<div><div class="columns-callout"><div><div>KDIGO guidelines recommend potassium binders as<br>a treatment option for RAASi-induced hyperkalemia<sup>7*</sup></div></div></div></div>
<div><p>* Practice points are consensus-based statements representing the expert judgment of the Work Group and are not graded. Although these statements are developed based on a different methodology, they should not be seen as "less important" or a "downgrade" from graded recommendations.<sup>7</sup></p><p>CKD=chronic kidney disease; HF=heart failure; RAASi=Renin-angiotensin-aldosterone system inhibitor; T2D=Type 2 diabetes.</p><p><strong>References:</strong></p><ol>
<li>Tobe SW, et al. Chronic kidney disease in diabetes: A clinical practice guideline. <em>Can J Diabetes.</em> 2025;49:73-86.</li>
<li>Kovesdy CP. Updates in hyperkalemia: Outcomes and therapeutic strategies. <em>Rev Endocr Metab Disord.</em> 2017;18(1):41-47.</li>
<li>Michel A, et al. Risk factors for hyperkalemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. <em>European Journal of Heart Failure.</em> 2015;17:205-213.</li>
<li>Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. <em>N Engl J Med.</em> 2015;372:211-221.</li>
<li>National Kidney Foundation. Clinical update on hyperkalemia. A chronic risk for CKD patients and a potential barrier to recommended CKD treatment. 2014. https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf Accessed April 11, 2025.</li>
<li>McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <em>Eur Heart J.</em> 2021 Sep 21;42(36):3599-3726.</li>
<li>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. <em>Kidney Int.</em> 2024;105(4S):S117-S314.</li>
</ol></div>